Navigation Links
Yale test detects early stage ovarian cancer with 99 percent accuracy
Date:2/12/2008

Researchers at Yale School of Medicine have developed a blood test with enough sensitivity and specificity to detect early stage ovarian cancer with 99 percent accuracy.

Results of this new study are published in the February 15 issue of the journal Clinical Cancer Research. The results build on work done by the same Yale group in 2005 showing 95 percent effectiveness of a blood test using four proteins.

The ability to recognize almost 100 percent of new tumors will have a major impact on the high death rates of this cancer, said Mor. We hope this test will become the standard of care for women having routine examinations.

Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the silent killer.

This new phase II clinical trial led by Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, included 500 patients; 350 healthy controls and 150 ovarian cancer patients. Mor and colleagues validated the previous research and used a new platform called multiplex technology to simplify the test into one single reaction using very small amounts of serum from the blood. The new platform uses six protein biomarkers instead of four, increasing the specificity of the test from 95 to 99.4 percent. The team looked for the presence of specific proteins and quantified the concentration of those proteins in the blood.

The Early Detection Research Network (EDRN) of the National Cancer Institute (NCI) independently evaluated the results of the test.

This is the most sensitive and specific test currently available, said Mor. Previous tests recognized 15 to 20 percent of new tumors. Proteins from the tumors were the only biomarkers used to test for ovarian cancer. That is okay when you have big mass
'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Test Detects Sensitivity to HIV Drug
2. McMaster test detects the most prevalent respiratory viruses
3. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
4. Blood protein detects lung cancer, even at earliest stage
5. New technique detects specific chromosomal damage, may indicate lung cancer risk
6. New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment
7. JCI online early table of contents: Feb. 7, 2008
8. New study suggests link between environmental toxins and early onset puberty in girls
9. A Reminder to Parents: Early Dental Visits Essential to Childrens Health
10. Rheumatoid arthritis sends many into early retirement
11. Early detection critical in treating pediatric thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Yale test detects early stage ovarian cancer with 99 percent accuracy
Yale test detects early stage ovarian cancer with 99 percent accuracy
Breaking Medicine News(10 mins):Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 2Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 3Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Spring Hill, TN Announces Its Grand Opening 5Health News:Registered Dietitians Identify Diet 'Gaps' - and How to Handle Them 2Health News:Registered Dietitians Identify Diet 'Gaps' - and How to Handle Them 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 2Health News:Nutraceutical Reports Fiscal 2009 Year End Results 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 4Health News:Nutraceutical Reports Fiscal 2009 Year End Results 5Health News:Nutraceutical Reports Fiscal 2009 Year End Results 6Health News:Nutraceutical Reports Fiscal 2009 Year End Results 7Health News:Nutraceutical Reports Fiscal 2009 Year End Results 8Health News:Fastrack Announces Major Expansion 2Health News:Fastrack Announces Major Expansion 3
Breaking Medicine Technology:Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 2Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 4Springer launches SpringerImages 9172 1Springer launches SpringerImages 9172 2Improving Care for Cardiac Patients is Centerpiece of American Society of Nuclear Cardiology Meeting 51101 1Improving Care for Cardiac Patients is Centerpiece of American Society of Nuclear Cardiology Meeting 51101 2American Optometric Association Supports New Federal Health Report Findings 3A Vision Screening Methods for Seniors are Lacking 51097 1American Optometric Association Supports New Federal Health Report Findings 3A Vision Screening Methods for Seniors are Lacking 51097 2American Optometric Association Supports New Federal Health Report Findings 3A Vision Screening Methods for Seniors are Lacking 51097 3
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3